9 Meters Biopharma Inc. [NASDAQ: NMTR] traded at a low on 04/29/21, posting a -3.20 loss after which it closed the day’ session at $1.21. The company report on April 21, 2021 that 9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit.
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced that management will participate in the 7th Annual Truist Securities Life Sciences Summit and invites investors to participate in one-on-one meetings. Please see additional details below:
Truist Securities 7th Annual Life Sciences Summit.
The results of the trading session contributed to over 3475553 shares changing hands. Over the past one week, the price volatility of 9 Meters Biopharma Inc. stands at 7.32% while the volatility over the past one month is 7.77%.
The market cap for NMTR stock reached $289.36 million, with 216.07 million shares outstanding and 180.50 million shares in the current float. Compared to the average trading volume of 7.76M shares, NMTR reached a trading volume of 3475553 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about 9 Meters Biopharma Inc. [NMTR]?
The Average True Range (ATR) for 9 Meters Biopharma Inc. is set at 0.11 The Price to Book ratio for the last quarter was 6.05, with the Price to Cash per share for the same quarter was set at 0.16.
How has NMTR stock performed recently?
9 Meters Biopharma Inc. [NMTR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.31. With this latest performance, NMTR shares dropped by -11.03% in over the last four-week period, additionally plugging by 72.46% over the last 6 months – not to mention a rise of 69.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NMTR stock in for the last two-week period is set at 47.74, with the RSI for the last a single of trading hit 52.03, and the three-weeks RSI is set at 46.63 for 9 Meters Biopharma Inc. [NMTR]. The present Moving Average for the last 50 days of trading for this stock 1.4263, while it was recorded at 1.2060 for the last single week of trading, and 1.0180 for the last 200 days.
9 Meters Biopharma Inc. [NMTR]: Deeper insight into the fundamentals
Return on Total Capital for NMTR is now -165.11, given the latest momentum, and Return on Invested Capital for the company is -541.91. Return on Equity for this stock declined to -545.95, with Return on Assets sitting at -276.67. When it comes to the capital structure of this company, 9 Meters Biopharma Inc. [NMTR] has a Total Debt to Total Equity ratio set at 0.72. Additionally, NMTR Total Debt to Total Capital is recorded at 0.71, with Total Debt to Total Assets ending up at 0.59. Long-Term Debt to Equity for the company is recorded at 0.52, with the Long-Term Debt to Total Capital now at 0.52.
Reflecting on the efficiency of the workforce at the company, 9 Meters Biopharma Inc. [NMTR] managed to generate an average of -$5,124,707 per employee.9 Meters Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.70 and a Current Ratio set at 5.70.
Earnings analysis for 9 Meters Biopharma Inc. [NMTR]
With the latest financial reports released by the company, 9 Meters Biopharma Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NMTR.
Insider trade positions for 9 Meters Biopharma Inc. [NMTR]
There are presently around $76 million, or 26.40% of NMTR stock, in the hands of institutional investors. The top three institutional holders of NMTR stocks are: ORBIMED ADVISORS LLC with ownership of 25,716,755, which is approximately 0% of the company’s market cap and around 1.00% of the total institutional ownership; ADAGE CAPITAL PARTNERS GP, L.L.C., holding 13,000,000 shares of the stock with an approximate value of $16.25 million in NMTR stocks shares; and VANGUARD GROUP INC, currently with $8.99 million in NMTR stock with ownership of nearly 839.418% of the company’s market capitalization.
Positions in 9 Meters Biopharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 36 institutional holders increased their position in 9 Meters Biopharma Inc. [NASDAQ:NMTR] by around 32,251,467 shares. Additionally, 13 investors decreased positions by around 1,476,439 shares, while 14 investors held positions by with 27,253,329 shares. The mentioned changes placed institutional holdings at 60,981,235 shares, according to the latest SEC report filing. NMTR stock had 20 new institutional investments in for a total of 21,914,582 shares, while 7 institutional investors sold positions of 345,520 shares during the same period.